Lateral Flow Assay for HIV Infection Timing Classification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV detection methods, especially in resource-limited settings, face challenges with accuracy, speed, and accessibility, particularly in distinguishing between recent and long-term infections, and require improvements for early identification and prevention of disease transmission.
Innovation Solution
A single-use, point-of-care, visually read, in vitro immunoassay using rIDR-M antigens in lateral flow assays that can detect HIV-1 and HIV-2 antibodies, enabling rapid classification of recent versus long-term infections in biological specimens like saliva, blood, and urine, with results obtainable within 1-45 minutes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If commercial HIV immunoassays are used, then detection can be performed, but sensitivity is insufficient for detecting recent infections with low antibody titers
Solution Approach 1:
The patent modifies the detection parameters by using less sensitive assay conditions and limiting antigen amounts to enable detection of low antibody titers characteristic of recent infections, while maintaining reliability through the use of recombinant proteins with major variant coverage
Solution Approach 2:
The patent introduces recombinant proteins (rIDR-M, rIDR-O, rIDR-N) as intermediary antigens that capture a broad spectrum of HIV antibody responses, serving as mediators between the assay system and diverse HIV subtypes to improve both sensitivity and reliability across different infection stages
2Measurement precision
If subtype-specific antigens are used in assays, then detection accuracy for that subtype improves, but bias against other subtypes increases
Solution Approach 1:
The patent creates universal recombinant proteins that function across multiple HIV subtypes by incorporating immunodominant regions from diverse genetic sequences, allowing a single assay to accurately detect antibodies against multiple subtypes without subtype-specific bias
Solution Approach 2:
The patent constructs composite antigens by combining immunodominant regions from different HIV subtypes into recombinant proteins, creating a multi-component antigen system that recognizes diverse antibody responses while maintaining consistent performance across subtypes
3Productivity
If rapid testing is implemented, then testing rates and early detection improve, but ability to distinguish recent from long-term infections is reduced
Solution Approach 1:
The patent performs preliminary classification by incorporating both recent infection markers (immunodominant regions) and long-term infection markers (conserved regions) into the same assay system, enabling upfront differentiation without requiring sequential testing
Solution Approach 2:
The patent segments the detection function into distinct detection zones within the assay, with specific recombinant proteins targeted to detect recent infection antibodies and others targeted to detect long-term infection antibodies, allowing simultaneous classification in a single rapid test
4Measurement precision
If laboratory-based testing is used, then diagnostic accuracy is high, but accessibility in resource-limited settings is poor
Solution Approach 1:
The patent employs disposable rapid test devices that eliminate the need for expensive, complex laboratory infrastructure, allowing accurate HIV detection and classification to be performed in remote settings without compromising diagnostic quality while dramatically improving accessibility
Solution Approach 2:
The patent replaces complex laboratory mechanical systems (centrifuges, washers, plate readers) with simplified immunochromatographic technology that relies on capillary action and visual readout, maintaining diagnostic accuracy while enabling operation in resource-limited environments
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides rapid, accurate, and simple HIV detection, enhancing early identification and treatment, reducing disease transmission, and improving public health monitoring, especially in remote areas with limited medical facilities.
Implementation Method 1
A single-use, point-of-care, visually read, in vitro immunoassay using rIDR-M antigens in lateral flow assays that can detect HIV-1 and HIV-2 antibodies
Data Source
AI summary
Devices, methods and test kits for the detection of Human Immunodeficiency Virus Type (HIV) infection are disclosed. The methods comprise the use of single use, qualitative, manually performed, visually read, in vitro immunoassays for the detection of antibodies to Human Immunodeficiency Virus Type 1 (HIV-1) and Type 2 (HIV-2); the immunoassays enable distinguishing between recent and long-term infection in HIV-1 infected subjects. The assay is a point of care (POC) test intended for use with blood or serum/plasma specimens.